RT Journal Article
SR Electronic
T1 SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 018515
DO 10.1101/018515
A1 Adwait Sathe
A1 Yu-An Zhang
A1 Xiaotu Ma
A1 Pradipta Ray
A1 Daniela Cadinu
A1 Yi-Wei Wang
A1 Xiao Yao
A1 Xiaoyun Liu
A1 Hao Tang
A1 Yunfei Wang
A1 Ying Huang
A1 Changning Liu
A1 Jin Gu
A1 Martin Akerman
A1 Yifan Mo
A1 Chao Cheng
A1 Zhenyu Xuan
A1 Lei Chen
A1 Guanghua Xiao
A1 Yang Xie
A1 Luc Girard
A1 Hongyang Wang
A1 Stephen Lam
A1 Ignacio I Wistuba
A1 Li Zhang
A1 Adi F Gazdar
A1 Michael Q Zhang
YR 2015
UL http://biorxiv.org/content/early/2015/08/05/018515.abstract
AB Aberrant DNA methylation has long been implicated in cancers. In this work we present a highly discriminative DNA methylation biomarker for non-small cell lung cancers and fourteen other cancers. Based on 69 NSCLC cell lines and 257 cancer-free lung tissues we identified a CpG island in SCT gene promoter which was verified by qMSP experiment in 15 NSCLC cell lines and 3 immortalized human respiratory epithelium cells. In addition, we found that SCT promoter was methylated in 23 cancer cell lines involving >10 cancer types profiled by ENCODE. We found that SCT promoter is hyper-methylated in primary tumors from TCGA lung cancer cohort. Additionally, we found that SCT promoter is methylated at high frequencies in fifteen malignancies and is not methylated in ∼1000 non-cancerous tissues across >30 organ types. Our study indicates that SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers.